"Jeffrey Holford, Jefferies LLC, Research Division - Equity Analyst [21]
--------------------------------------------------------------------------------
Just wondering if you can just give us a little bit more color on DARZALEX. I guess, I'm actually talking about in the U.S., whether you'll have better information hopefully. Just your market share in the lines of therapy that you're in and what kind of duration of therapy you think you're going to get to in those lines?
--------------------------------------------------------------------------------
Joaquin Duato, Johnson & Johnson - Executive VP & Worldwide Chairman of Pharmaceuticals [22]
--------------------------------------------------------------------------------
Thank you. So as far as DARZALEX, as I commented, our market share in third line class is north of 40% in the U.S. already, and in second line, depending on the shortage, generally north of 20%, and it continues to grow. Our -- the trends that we are seeing in the market are very positive, particularly, after the approval in one prior line and the data we presented in one prior line, and also, as I commented earlier, we already finished the study in first line in combination with BMP, and we are planning to file before the end of the year. So all is positive on that side.
Importantly, we are also working, as you guys know, in developing a subcu formulation, and we are going to start our Phase III study with a subcu formulation this year. So increasingly, we see daratumumab, DARZALEX becoming a backbone therapy in the treatment of multiple myeloma, and that's the feedback that we are getting from customers."
News 
Market Data 
Discover 
